TAKARA BIO INC.【JP:4974】Stock Price

Takara Bio operates in four business segments: reagents, instruments, contract services, and gene therapy. These businesses leverage biotechnology and primarily serve universities, research institutions, and companies as customers. Products and services are distributed through sales agents, with added value provided through technical seminars and other support.

In the reagents, instruments, and contract services segments, the company provides DNA/RNA analysis products and stem cell-related products based on technologies such as PCR, cloning, and gene transfection. As a CDMO provider, it offers contract manufacturing for regenerative medicine products and gene analysis services.

In the reagent field, Takara Bio launched Japan's first domestically produced restriction enzyme in 1979 and continues developing research reagents for genetic engineering. The company has expanded its product portfolio with brands including Clontech and Cellartis, and strengthened offerings in ultra-trace nucleic acid sample analysis and spatial transcriptomics.

In the instruments field, the company began importing and selling thermal cyclers—essential for PCR—in 1988 and has since developed proprietary PCR equipment. It has acquired companies with single-cell analysis technology to strengthen manufacturing and sales capabilities.

In contract services, the company focuses on CDMO contracts that cover process development through manufacturing of regenerative medicine, cell therapy, and gene therapy products. For gene analysis and testing services, it provides large-scale genome analysis and genetic testing using next-generation sequencing.

In the gene therapy field, the company applies genetic engineering technology to maximize the value of its drug discovery platform. It develops gene therapy drugs and manufactures and sells adjuvants for mRNA vaccines. As a clinical development project, it is advancing engineered T-cell therapy.

As a subsidiary of Takara Holdings, Takara Bio operates as a specialized biotechnology business. Within the group, it develops, manufactures, and sells reagents and instruments while expanding operations across regions.

Takara Bio's corporate mission is to contribute to people's health through the development of innovative biotechnology. The company leverages biotechnology centered on gene therapy, and aims to create social value and enhance corporate value through its reagents and instruments business and its CDMO (Contract Development and Manufacturing Organization) business.

The company has formulated its "Long-Term Management Vision 2025" and aims to become a drug discovery company that continuously creates new modalities through its reagents and instruments business and CDMO business. In 2023, it announced its "Medium-Term Management Plan 2025" and is advancing concrete implementation strategies.

As a growth strategy, Takara Bio is expanding its business domains and developing new technologies. The company is broadening its operations from academia to industrial applications, clinical-related fields, and drug discovery, while advancing new product development in research reagents and CDMO business.

Under the "Medium-Term Management Plan 2025," the company is establishing its position as a global platform provider in the life sciences industry, strengthening its manufacturing and marketing infrastructure, and enhancing quality control. It is also maximizing the value of its drug discovery platform technologies and accelerating new product development.

As a management foundation strengthening measure, Takara Bio aims to improve ROE through investments in growth areas and shareholder returns. Furthermore, the company seeks to deepen connections with employees and achieve both the realization of a sustainable society and the company's sustained growth.

Takara Bio uses consolidated operating profit and ROE as quantitative targets, and employs revenue and research and development expenses as KPIs to drive business growth. To realize sustained growth, the company is implementing measures with a sense of speed.